The MUST trial is a randomized controlled clinical trial comparing two treatments for patients with vision-threatening non-infectious intermediate uveitis, posterior uveitis, or panuveitis: local therapy with fluocinolone acetonide intraocular implant in affected eyes; versus standard therapy: systemic corticosteroid therapy supplemented, when indicated, by corticosteroid-sparing potent immunomodulator therapy.
Between 2011 (the first year a MUST paper was published) and 2017, the American Uveitis Society selected 76 papers as the top papers of the year for training purposes. The MUST Trial and Follow-up Study have contributed 14 of these papers (18.4%).
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.